BCL2 and early-onset autosomal dominant Alzheimer disease: These inhibitors have shown efficacy in treating proliferative tumors, such as acute myeloid leukemia,32 and diseases associated with cellular senescence, such as diabetes33 and Alzheimer’s disease.34 We propose that BCL2 inhibitors can eliminate both proliferative and senescent GCMN cells due to their high BCL2 expression.